Form 4: Intuitive Surgical SVP Sells Shares Under 10b5-1 Plan

Intuitive Surgical's SVP & Chief Manufacturing and Supply Chain, Mark Brosius, reported the exercise of stock options and subsequent sale of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Mark Brosius, SVP & Chief Manufacturing and Supply Chain at Intuitive Surgical Inc. (ISRG), reported transactions involving company stock.
• On December 12, 2025, Brosius exercised 4,500 non-qualified stock options at an exercise price of $79.6378 per share.
• Concurrently on December 12, 2025, he sold 4,500 shares of common stock at a price of $547.36 per share.
• An additional 464 shares of common stock were sold on December 15, 2025, at a price of $548.49 per share.
• All reported transactions were conducted in accordance with a Rule 10b5-1 trading plan.
• Following these transactions, Brosius beneficially owns 443 shares of common stock.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (option exercise and sale) under a pre-arranged 10b5-1 plan. This is a neutral event, reflecting personal financial management rather than a specific positive or negative signal about the company's operational performance or future prospects.

Positives

• The exercise of stock options at a significantly lower price ($79.6378) compared to the sale price (over $547) indicates the substantial value appreciation of the company's stock.
• The use of a Rule 10b5-1 trading plan demonstrates pre-planned transactions, which enhances transparency and mitigates concerns about opportunistic insider trading.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by some investors, although it is often for personal financial management.

Future Outlook

The Rule 10b5-1 trading plan, under which these transactions occurred, is set to expire on February 14, 2027. The non-qualified stock option, granted pursuant to the 2010 Incentive Award Plan, vests 1/8th six months after the date of grant and 1/48th monthly thereafter, with an expiration date of February 15, 2027.

Management Comments

• The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.

Industry Context

Insider transactions, particularly those involving option exercises and subsequent sales under Rule 10b5-1 plans, are common across all industries. They typically reflect personal financial planning rather than a specific outlook on the company's immediate future, especially for executives in mature, high-growth sectors like medical technology.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor impact. Routine insider sales under a 10b5-1 plan are generally not seen as a strong signal for future stock performance but provide transparency into executive compensation and personal financial planning.

Next Steps

• The Rule 10b5-1 trading plan will continue until its expiration on February 14, 2027.
• The remaining non-qualified stock options will continue to vest according to the schedule: 1/8th six months after the grant date and 1/48th monthly thereafter, until their expiration on February 15, 2027.

Key Dates

Keywords

Intuitive Surgical, ISRG, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, Mark Brosius, 10b5-1 Plan, Corporate Governance